JC02 Rec'd PCT/PTO 22 MR 2002

| (REV. 11-2000) U.S. DEPARTMENT OF CO. | MMERCE PATENT AND TRADEMARK OFFICE | ATTORNEY 'S DOCKET NUMBER | | | | | | | |
|---|---|---|--|--|--|--|--|--|--|
| TRANSMITTAL LETTER | TRANSMITTAL LETTER TO THE UNITED STATES | | | | | | | | |
| DESIGNATED/ELECT | U.S. APPLICATION NO. (If known, see 37 CFR 1.5 10/088885 | | | | | | | | |
| | CONCERNING A FILING UNDER 35 U.S.C. 371 | | | | | | | | |
| INTERNATIONAL APPLICATION NO. PCT/EP00/08890 | INTERNATIONAL FILING DATE 12 September 2000 (12.09.00) | PRIORITY DATE CLAIMED 24 September 1999 (24.09.99) | | | | | | | |
| TITLE OF INVENTION USE OF SUBSTITUTED 4-BIARYLBUTYRIC AND 5-BIARYLPENTANOIC ACID DERIVATIVES FOR THE TREATMENT OF MULTIPLE SCLEROSIS | | | | | | | | | |
| APPLICANT(S) FOR DO/EO/US | | | | | | | | | |
| FAHRIG, et al. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | | | | | | | |
| 1. X This is a FIRST submission of item | 1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | |
| 2. This is a SECOND or SUBSEQUE | 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. | | | | | | | | |
| This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. | | | | | | | | | |
| 4. X The US has been elected by the expiration of 19 months from the priority date (Article 31). | | | | | | | | | |
| 5. X A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. X is attached hereto (required only if not communicated by the International Bureau). | | | | | | | | | |
| | | | | | | | | | |
| · = | | | | | | | | | |
| 6. An English language translation of t | 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). | | | | | | | | |
| a. is attached hereto. | | | | | | | | | |
| | itted under 35 U.S.C. 154(d)(4). | 25 H C C 251(.)(2)) | | | | | | | |
| | | | | | | | | | |
| <u> </u> | by the International Bureau. | mai Burcau). | | | | | | | |
| | ver, the time limit for making such amendme | nts has NOT expired | | | | | | | |
| d. X have not been made and w | _ | | | | | | | | |
| _ | ne amendments to the claims under PCT Artic | ele 19 (35 U.S.C. 371 (c)(3)). | | | | | | | |
| 9. X An oath or declaration of the invento | or(s) (35 U.S.C. 371(c)(4)). | | | | | | | | |
| 10. An English lanugage translation of the Article 36 (35 U.S.C. 371(c)(5)). | ne annexes of the International Preliminary E | xamination Report under PCT | | | | | | | |
| Items 11 to 20 below concern documen | t(s) or information included: | | | | | | | | |
| 11. X An Information Disclosure Statem | | | | | | | | | |
| 12. An assignment document for recor | ding. A separate cover sheet in compliance v | vith 37 CFR 3.28 and 3.31 is included. | | | | | | | |
| 13. X A FIRST preliminary amendment. | | | | | | | | | |
| 14. A SECOND or SUBSEQUENT pr | reliminary amendment. | | | | | | | | |
| 15. A substitute specification. | | | | | | | | | |
| 16. A change of power of attorney and | /or address letter. | | | | | | | | |
| 17. A computer-readable form of the se | equence listing in accordance with PCT Rule | 13ter.2 and 35 U.S.C. 1.821 - 1.825. | | | | | | | |
| 18. A second copy of the published int | ernational application under 35 U.S.C. 154(d |)(4). | | | | | | | |
| 19. A second copy of the English language | uage translation of the international application | on under 35 U.S.C. 154(d)(4). | | | | | | | |
| 3) Inf : | ificat f Mailing under 37 C.F.R. 1.10; esmittal f Informati n Disclosure Stateme rmati n Disclosur Citati n (M dified Form ırn R ceipt Postcard. | | | | | | | | |
| Date of Deposit: 22 March 2002 Express Mail Label N : FT131980172US | | | | | | | | | |

| U.S. APPLICATION TO (if) the | 8880 | 85 ¹ | PCT/EP00/08890 | | ATTORNEY'S DOCKET NUMBER Le A 33 914 | | |
|--|----------------------------------|-------------------------------|--|------------------------------|---------------------------------------|-----------------------|--------------|
| | ving fees are su | | | | CAL | | PTO USE ONLY |
| BASIC NATIONAL | | | (1) - (5)): | | 1 | | |
| Neither internation | nal preliminar | y examinati | ion fee (37 CFR 1.482) | | l | | |
| nor international se and International S | earch fee (37 (Search Report | CFR 1.445(not prepare | (a)(2)) paid to USPTO ed by the EPO or JPO | \$1000.00 | | | |
| International prelin USPTO but Intern | minary examinational Search | nation fee (3 n Report pro | 37 CFR 1.482) not paid to epared by the EPO or JPC | \$ 860.00 - | | | |
| International prelin | ninary examin | nation fee (| 37 CFR 1.482) not paid to | USPTO \$890.00 | | | |
| but international se | earch fee (37 C | CFR 1.445(| a)(2)) paid to ÚSPŤO | \$710.00 | | | |
| but all claims did n | ot satisfy prov | visions of P | 37 CFR 1.482) paid to US PCT Article 33(1)-(4) | \$690.00 | | | |
| International prelin | ninary examin | ation fee (3 | 37 CFR 1.482) paid to US article 33(1)-(4) | SPTO \$100.00 | | | _ |
| | | | BASIC FEE AMO | | \$ 89 | 0.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than 20 months from the earliest claimed priority date (37 CFR 1.492(e)). | | | | | \$ | | |
| CLAIMS | NUMBER | FILED | NUMBER EXTRA | RATE | \$ | | |
| Total claims | 8 | - 20 = | 0 | x \$18.00 | \$ 00 | .00 | |
| Independent claims | 4 | -3 = | 1 | x \$80.00 84.00 | \$ 84 | | |
| MULTIPLE DEPEN | | | | + \$ 270.00 280.0 | | | |
| | | | OF ABOVE CALCU | | \$ 97 | 4.00 | |
| Applicant claim are reduced by | is small entity 1/2. | status. See | e 37 CFR 1.27. The fees | indicated above + | \$ | | |
| | | | | JBTOTAL = | \$ 97 | 4.00 | |
| Processing fee of \$1. months from the earl | 30.00 for furn liest claimed p | ishing the loriority date | English translation later the (37 CFR 1.492(f)). | nan 20 30 | \$ | | |
| TOTAL NATIONAL FEE = | | | \$ 97 | 4.00 | | | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + | | | | \$ | | , | |
| TOTAL FEES ENCLOSED = | | | | \$ 97 | 4.00 | | |
| | | | | | | unt to be efunded: | \$ |
| | | | | | | charged: | \$ |
| a. A check in the amount of \$ to cover the above fees is enclo | | | | | | | • |
| <u> </u> | | | - | | | | |
| b. Please charge my Deposit Account No. 13-3372 in the amount of \$ 974.00 to cover the above fees. A duplicate copy of this sheet is enclosed. | | | | | | | |
| A dapheate copy of this sheet is chelosed. | | | | | | | |
| c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-3372. A duplicate copy of this sheet is enclosed. | | | | | | | |
| d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | | | |
| information | a should not t | e included | on this form. Provide of | redit card information | and a | uthorization on | PTO-2038. |
| Nome wil | | | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status. | | | | | | | e (37 CFR |
| SEND ALL CORRESPO | ONDENCE TO: | | | , i | 1.,, | · _ la | _ |
| Jeffrey M. Greenman Signature | | | | | | ay | |
| Vice President, Patents and Licensing | | | | | rav | / | |
| Bayer C rporatio | | | | William NAME | | <u> </u> | |
| 400 Morgan Lane West Haven, CT (| | | | | | | |
| • | | | | 31,018 REGISTRA | REGISTRATION NUMBER | | |
| | | | | REGISTRA | I I IOI I | ONIDER | |

Attorney's Docket No. Le A 33 914

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Fahrig, et al.

Serial No.: National Stage Filing of PCT/EP00/08890

Filed: herewith

For: Use of Substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the

Treatment of Multiple Sclerosis

BOX PCT Assistant Commissioner for Patents Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 CFR 1.10

I hereby certify that the attached correspondence comprising:

- Transmittal Letter to the United States Designated/Elected Office (DO/EO/US)
 Concerning a Filing under 35 U.S.C. 371 [IN DUPLICATE];
- Preliminary Amendment;
- Original Combined Declaration and Power of Attorney;
- Copy of the International Application as filed (35 U.S.C. 371(c)(2));
- Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98 consisting of Transmittal of Information Disclosure Statement under 37 C.F.R. 1.97(b), Information Disclosure Citation (Modified Form PTO-1449) and copies of references cited therein; and
- Return Receipt Post Card.

is, on the date shown below, being deposited with the United States Postal Service, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET131980172US, addressed to:

Box PCT Assistant Commissioner for Patents Washington, D.C. 20231

22 MARCH 2002

Date

Signature of Person Certifying / Beatriz Alviz